ReviewPediatric gastroenterology, hepatology & nutrition2019
The Role of Two Human Milk Oligosaccharides, 2'-Fucosyllactose and Lacto-N-Neotetraose, in Infant Nutrition.
Review in Pediatric gastroenterology, hepatology & nutrition, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 127 citations in OpenAlex.
- Effects of Human Milk Oligosaccharide 2'-Fucosyllactose Ingestion on Weight Loss and Markers of Health.Nutrients · 2024Trial
- Iron Absorption from an Iron-Fortified Follow-Up Formula with and without the Addition of a Synbiotic or a Human-Identical Milk Oligosaccharide: A Randomized Crossover Stable Isotope Study in Young Thai Children.The Journal of nutrition · 2024Trial
- Trial
- Analysis of immune, microbiota and metabolome maturation in infants in a clinical trial of Lactobacillus paracasei CBA L74-fermented formula.Nature communications · 2020Trial
- Cesarean section-induced changes in the gut microbiota facilitate metabolic disease in high-fat diet-induced obese mice.Microbiome · 2026Article
- Analysis of the Milk Oligosaccharides Spectrum and Sialylation Status of Milk from West African Dwarf Goat and East Friesian Sheep.ACS omega · 2026Article
- Expanding the Toolbox for Inducible Protein Expression With Automation-enabled Generation of Glycomimetics.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026Article
- Childhood obesity, dietary patterns and gut microbiota: a narrative review.Journal of physiology and biochemistry · 2026Review
- Breastfeeding and infant gut microbiota: influence of bioactive components.Gut microbes · 2025Review
- The microbiome's hidden influence: preclinical insights into inflammatory responses in necrotizing enterocolitis.Seminars in immunopathology · 2025Review
- Supplementation of 2'-Fucosyllactose in Formula-Fed Infants Has Potential Benefits to Reduce the Risks of Infantile Colic and Atopic Dermatitis in Infancy.Pediatric gastroenterology, hepatology & nutrition · 2025Article
- Comparative Analysis of Breastfeeding and Infant Formulas: Short- and Long-Term Impacts on Infant Nutrition and Health.Food science & nutrition · 2025Review
- Emerging gut microbial glycoside hydrolase inhibitors.RSC chemical biology · 2025Review
- Human milk oligosaccharide secretion dynamics during breastfeeding and its antimicrobial role: A systematic review.World journal of clinical pediatrics · 2025Article
- The Impact of Human Milk Oligosaccharides on Antibiotic-Induced Microbial Dysbiosis and Gut Inflammation in Mice.Antibiotics (Basel, Switzerland) · 2025Article
- Growth and gastrointestinal tolerance of healthy formula-fed infants: a multicentre, prospective observational study.BMC pediatrics · 2025Observational
- A review of human milk oligosaccharide concentrations of breast milk for infants and young children through 24 months of age.Frontiers in pediatrics · 2025Review
- Glycosyltransferases: glycoengineers in human milk oligosaccharide synthesis and manufacturing.Frontiers in molecular biosciences · 2025Review
- The early-life gut microbiome in common pediatric diseases: roles and therapeutic implications.Frontiers in nutrition · 2025Review
- Unveiling the neonatal gut microbiota: exploring the influence of delivery mode on early microbial colonization and intervention strategies.Archives of gynecology and obstetrics · 2024Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human breast milk contains numerous biomolecules. Human milk oligosaccharides (HMOs) are the third most abundant component of breast milk, after lactose and lipids. Amongst the synthetized HMOs, 2'-fucosyllactose (2'-FL) and lacto-N-neotetraose (LNnT) are widely studied and are considered safe for infant nutrition. Several studies have reported the health benefits of HMOs, which include modulation of the intestinal microbiota, anti-adhesive effect against pathogens, modulation of the intestinal epithelial cell response, and development of the immune system. The amount and diversity of HMOs are determined by the genetic background of the mothers (HMO secretors or non-secretors). The non-secretor mothers secrete lower HMOs than secretor mothers. The breastfed infants of secretor mothers gain more health benefit than those of non-secretor mothers. In conclusion, supplementation of infant formula with 2'-FL and LNnT is a promising innovation for infant nutrition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.